Plasma pTau217 Cutoffs for Clinical Use - Top_Thought_Leaders - MDSpire

Plasma pTau217 Cutoffs for Clinical Use

Researchers assess how biological factors influence plasma biomarker interpretation for amyloid detection.

  • By

  • Kathryn Wighton

  • February 4, 2026

  • 4 min

Share

Top Thought Leaders in Neurology

Brief introduction explaining scope and methodology.

Original Source(s)

Plasma pTau217 Cutoffs for Clinical Use

  • by Kathryn Wighton

  • February 4, 2026

Related Content

IPS Could Minimize GI Effects in Treating Iron Deficiency

Review summarizes pharmacokinetic and clinical data on iron protein succinylate across patients with iron deficiency and iron deficiency anemia.

Medical Oddities: Can a Home Be Preventive Care?

This week’s medical plot twists involved ants, architecture, and auditory hallucinations.

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.